http://purl.org/np/RA2-dISS3g... RA2-dISS3g

links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance

http://www.w3.org/ns/prov#wasAttributedTo wasAttributedTo

https://orcid.org/0000-0002-3668-2627 Elif Ozkan

Elif Ozkan

2022-10-13T11:44:43.063Z

http://purl.org/np/RA2-dISS3g... RA2-dISS3g

links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance

http://www.w3.org/ns/prov#generatedAtTime generatedAtTime

2022-10-13T11:44:43.063138

Elif Ozkan

2022-10-13T11:44:43.063Z

http://purl.org/np/RA2-dISS3g... RA2-dISS3g

links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance

http://www.w3.org/ns/prov#wasQuotedFrom wasQuotedFrom

Nebivolol tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. The largest and most consistent cardiovascular outcome benefit has been a reduction in stroke. There are no controlled trials demonstrating risk reduction with nebivolmolol tablets. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients.

Elif Ozkan

2022-10-13T11:44:43.063Z